We report a 31-year-old female patient with cutaneous sarcoidosis, who showed a complete remission of her single system skin disease after an 8-month therapy with oral isotretinoin (1 mg/kg/day). At 15-month follow-up, the patient still remained free of recurrence and visceral involvement. Key words: retinoids; skin; granuloma.

(Accepted April 22, 1998.)


S. Georgiou, Department of Dermatology, School of Medicine, University of Patras, P.O. Box 1413, GR-265 00, Rio-Patras, Greece.

Sarcoidosis is a multisystem disorder of unknown aetiology, most commonly affecting young adults and characterized by the occurrence of non-caseating epithelioid granulomas in all affected organs and distortion of normal tissue architecture (1, 2). The pathogenetic mechanisms of this disorder are far from being clearly understood; however, it is widely accepted that sarcoidosis may represent a macrophage-initiated and T-cell-mediated response to infectious antigens or autoantigens in genetically predisposed individuals (3–5). Skin involvement occurs in about 25% of the affected patients and may be the only manifestation of sarcoidosis (6). Diverse therapeutic approaches, including topical, intralesional and systemic steroids, antimalarials, methotrexate and thalidomide have been used in the management of cutaneous sarcoidosis, but no form of therapy has yielded consistently effective results (7–9).

We report herein a patient in whom treatment with oral isotretinoin resulted in a complete remission of cutaneous sarcoidosis.

CASE REPORT

A 31-year-old HIV-negative Caucasian woman presented to our Department with a 3-year history of violaceous nodules and plaques on the trunk and extremities. The clinical diagnosis of sarcoidosis had been histologically confirmed. The response of her skin lesions to previously administered unknown dosages of intralesional (6 months) and oral steroids (10 months) was disappointing. A subsequent 3-month course of hydroxychloroquine (200 mg/day) had been ineffective. In the 10 months prior to her admission to our Department, she had received no therapy.

Physical examination of the patient was remarkable only for multiple violaceous nodules and plaques on the trunk, the arms, the thighs and the knees; over the joints, the skin lesions revealed a waxy appearance at their central part and a purplish rim at the periphery (Fig. 1a). Histological examination of formalin-fixed, paraffin-embedded biopsy specimens obtained from the lesional skin revealed multiple, sharply demarcated sarcoïd granulomas in the papillary and middle dermis mainly consisting of epithelioid cells and several multinucleated giant cells, with no evidence of central necrosis. Examination of PAS- and Fite-stained sections failed to detect fungi or mycobacteria, respectively.

All results of routine laboratory investigations were within normal limits. Additionally, the serum levels of angiotensin converting enzyme (ACE), calcium, β2-microglobulin, gammaglobulins, immunoglobulins and the urine levels of calcium showed no abnormalities. A tuberculin skin test was negative. Chest and hand X-ray examination, pulmonary function tests, computed tomographic scan, ultrasound and ophthalmological examinations revealed no pathological findings.

Since both steroids and antimalarials had been ineffective in our patient, we decided to start a therapeutic trial with oral isotretinoin (Roaccutane, Roche Hellas S.A., Athens, Greece), considering the immunomodulatory effects of oral isotretinoin and the reported encouraging therapeutic results of this compound in cutaneous sarcoidosis (10, 11). Written consent was obtained from the patient subsequent to a thorough explanation of the possible therapeutic efficacy and toxicity of this retinoid.

Treatment was initiated with an oral isotretinoin dose of 1 mg/kg/day. About 3 weeks after the onset of treatment, no new lesions had developed, but the existing ones revealed no evidence of regression. Over the next 3 weeks the nodules and plaques started to flatten and fade. Further administration of the same isotretinoin dosage led to a gradual resolution of the skin lesions, which completely disappeared.

Fig. 1. Clinical aspect of skin lesions at the left knee before (a) and 15 months after (b) the start of therapy, showing only a residual hyperpigmentation.
8 months after the onset of the treatment (Fig. 1b). Post-treatment histo-
lological examination of biopsy specimens obtained from the lesional skin failed to reveal epithelioid granulomas or any evidence of sarco-
dosis. Only a few lymphohistiocytic cells around the vessels of the papillary dermis could still be seen in the apparently normal skin.

Apart from a moderate chelitis, dryness of the nasal mucosa and xero-
sis, the drug was well tolerated; moreover, the results of the laboratory investigations remained within normal limits throughout the treatment period, and the tuberculin skin test remained negative. At 15-month follow-up our patient was and presently continues to remain free of recurrence and of visceral involvement.

DISCUSSION
Oral isotretinoin represents an effective therapy for severe recalcitrant forms of acne, which is associated with predictable and mostly reversible adverse reactions (12, 13). Recent evidence suggests that, apart from the profound influence of isotretinoin on epithelial differentiation and proliferation, its immunomodulatory effects may also be involved in the mechanisms of its therapeutic action in acne and other cutaneous disorders (14–17).

The first clinical evidence that oral isotretinoin benefits patients with cutaneous sarcoidosis was reported in 1983 by Waldinger et al. (10). These authors treated a female patient suffering from chronic cutaneous and pulmonary sarcoidosis (unresponsive to oral corticosteroids) with 0.67–1.34 mg/kg/day oral isotretinoin over a period of 30 weeks. Interestingly, the skin lesions and the peripheral lymphadenopathy revealed a consistent improvement, whereas the pulmonary function tests remained unchanged. Moreover, the low WBC count and the increased serum ACE levels failed to become normal during the course of therapy.

Three years later (1986), Vaillant et al. (11) reported a female patient with cutaneous sarcoidosis unresponsive to oral corticos-
teroids, antimalarias and allopurinol. The response of the two skin lesions to a 6-month therapy with oral isotretinoin (0.4–1.0 mg/kg/day) was favourable: one completely resolved and the other reduced considerably in size. However, isotretinoin therapy exerted no effect on the lymphopenia and the impaired proliferative response of T-lymphocytes to various mitogens, observed in their patient prior to the onset of the treatment.

To our knowledge, the patient described in the present paper is the first to reveal a complete remission of cutaneous sarcoi-
dosis after oral isotretinoin therapy. The possibility that this impressive therapeutic response may represent a spontaneous remission of cutaneous sarcoidosis rather than a result of iso-
tretinoin administration cannot be definitely ruled out. Never-
theless, in view of the 3-year duration of the therapy-resistant and progressive disease that responded to this retinoid within the first 6 weeks of treatment, this possibility seems very unlikely. Our findings confirm the observations of Waldinger et al. (10) and Vaillant et al. (11), and indicate that oral isotretinoin may be regarded as an effective and safe alternative therapeutic approach to the management of cutaneous sarcoidosis.

The mechanisms underlying the therapeutic action of iso-
tretinoin in cutaneous sarcoidosis remain presently unknown; however, prostaglandin E2 (PGE2) is known to inhibit granu-
loma formation in the animal models of sarcoidosis (18–20). Moreover, the release of this prostaglandin by macrophages in this disorder is markedly decreased (21). On the other hand, the tumour necrosis factor (TNF) is thought to be involved in the pathogenesis of sarcoidosis (22), since it plays a significant role in experimental granuloma formation (23). Both its production by macrophages (24) and the plasma levels of their receptors (22) are markedly increased in this disease. It seems reasonable, therefore, to suggest that the ability of isotretinoin to stim-
ulate the production of PGE2 by macrophages (25) and/or to inhibit the production of TNF by these cells (26) and to down-
regulate the cell surface expression of TNF receptors (27) might be of importance for the therapeutic action of this retinoid in cutaneous sarcoidosis.

REFERENCES
5. Müller-Quernheim J. Immunologische Zellaktivierungen bei Sar-
9. Muthiah MM, Macfarlane JT. Current concepts in the manage-
11. Vaillant L, Le Marchand D, Bertrand S, Grangeponte MC, Lorette G. Sarcoidose cutanée annulaire du front: traitement par iso-
13. Tsaftasas D, Orfanos CE. Chemotherapy of psoriasis and other skin disorders with oral retinoids. In: Baden HP, ed. The chemo-
14. Sidell N, Conner MJ, Chang B, Lowe NJ, Borok M. Effects of 13-
19. Kunkel SL, Fantone JC; Ward PA, Zuerier RB. Modulation of

Acta Derm Venereol (Stockh) 78

20. Chensue SW, Kunkel SL, Ward PA, Higashi GI. Exogenous admin-
istered prostaglandins modulate pulmonary granulomas induced

cyclooxygenase products by alveolar macrophages in pulmonary

22. Nakayama T, Hashimoto S, Amemiya E, Horie T. Elevation of
plasma-soluble tumour necrosis factor receptors (TNF-R) in

23. Shikama Y, Kobayashi K, Yamagata N. Augmentation of pulmon-
ary foreign body granulomatous inflammation in mice by lipo-
poly saccharide: involvement of macrophage activation and tumor

24. Tero I, Hashimoto S, Horie T. Effect of GM-CSF on TNF-alpha
and IL-1 beta production by alveolar macrophages and peripheral
blood monocytes from patients with sarcoidosis. Int Arch Allergy

25. Levine L, Ohuchi K. Retinoids as well as tumor promoters
enhance deacylation of cellular lipids and prostaglandin produc-

26. Mehta K, McQueen T, Tucker S, Pandita R, Aggarwal BB. Inhibi-
tion by all-trans-retinoic acid of tumor necrosis factor and nitric

27. Totpal K, Chaturvedi MM, La Pushin R, Aggarwal BB. Retinoids
downregulate both p60 and p80 forms of tumor necrosis factor
receptors in human histiocytic lymphoma U-937 cells. Blood